Rating agencies warn Pfizer over $11.4bn Array Biopharma buy
Pfizer has agreed to buy US compatriot Array Biopharma for around $11.4bn in enterprise value in a heavily debt-driven acquisition. This has led to warning shots from the rating agencies.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts